Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders

The Lancet Neurology

Volumn 8, Issue 12, 2009, Pages 1140-1149

  Voon, Valerie ^a   Fernagut, Pierre Olivier ^b   Wickens, Jeff ^c   Baunez, Christelle ^d   Rodriguez, Manuel ^e,i   Pavon, Nancy ^f   Juncos, Jorge L ^g   Obeso, José A ^h,i   Bezard, Erwan ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

^d AIX MARSEILLE UNIVERSITY   (France)

^e Faculty of Medicine   (Spain)

^f CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DOPAMINE; LEVODOPA; ROPINIROLE; ROTIGOTINE;

BEHAVIOR DISORDER; BINGE EATING DISORDER; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COMPULSION; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINERGIC ACTIVITY; DYSKINESIA; HABIT; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LEARNING; NEUROTRANSMISSION; PALLIDOTOMY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANTIPARKINSON AGENTS; AUTOMATISM; COMPULSIVE BEHAVIOR; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; GAMBLING; HUMANS; IMPULSE CONTROL DISORDERS; LEVODOPA; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; SEXUAL BEHAVIOR;

EID: 72149094883     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70287-X     Document Type: Review

References (114)

1. Halliday G., Hely M., Reid W., and Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115 (2008) 409-415
2. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Rev Neurosci 2 (2001) 577-588
3. Obeso J.A., Merello M., Rodriguez-Oroz M.C., Marin C., Guridi J., and Alvarez L. Levodopa-induced dyskinesias in Parkinson's disease. Handb Clin Neurol 84 (2007) 185-218
4. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., and Goetz C.G. Levodopa-induced dyskinesias. Mov Disord 22 (2007) 1379-1389
5. Voon V., Hassan K., Zurowski M., et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67 (2006) 1254-1257
6. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., and Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 21 (2006) 2068-2072
7. Grosset K.A., Macphee G., Pal G., et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21 (2006) 2206-2208
8. Weintraub D., Siderowf A.D., Potenza M.N., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 (2006) 969-973
9. Evans A.H., Lawrence A.D., Potts J., Appel S., and Lees A.J. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65 (2005) 1570-1574
10. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., and Lees A.J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 (2000) 423-428
11. Pezzella F.R., Colosimo C., Vanacore N., et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20 (2005) 77-81
12. Evans A.H., Katzenschlager R., Paviour D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19 (2004) 397-405
13. Lawrence A.J., Blackwell A.D., Barker R.A., et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord 22 (2007) 2339-2345
14. Miyasaki J.M., Al Hassan K., Lang A.E., and Voon V. Punding prevalence in Parkinson's disease. Mov Disord 22 (2007) 1179-1181
15. Voon V., Hassan K., Zurowski M., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66 (2006) 1750-1752
16. Potenza M.N. Non-substance and substance addictions. Addiction 104 (2009) 1016-1017
17. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 (2000) S2-S9
18. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 7 (1992) 117-124
19. Rascol O., Brooks D.J., Korczyn A.D., et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 21 (2006) 1844-1850
20. Rose S., Scheller D.K., Breidenbach A., et al. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol 18 (2007) 155-160
21. Voon V., Potenza M.N., and Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol 20 (2007) 484-492
22. Diagnostic and Statistical Manual of Mental Disorders, Version IV (DSM-IV-RT) (1994), American Psychiatric Association, Washington, DC
23. McElroy S.L., Keck P.E., Pope H.G., Smith J.M., and Strakowski S.M. Compulsive buying: a report of 20 cases. J Clin Psychiatry 55 (1994) 242-248
24. Wong S.H., Cowen Z., Allen E.A., and Newman P.K. Internet gambling and other pathological gambling in Parkinson's disease: a case series. Mov Disord 22 (2007) 591-593
25. Weintraub D, Koester J, Potenza MN, et al. Dopaminergic therapy and impulse control disorders in Parkinson's disease: a cross-sectional study of over 3000 patients. 12th International Congress of Parkinson's Disease and Movement Disorders; Chicago, IL, USA; June 22-26, 2008. LB4.
26. Voon V., and Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64 (2007) 1089-1096
27. Molina J.A., Sainz-Artiga M.J., Fraile A., et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord 15 (2000) 869-872
28. Ondo W.G., and Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 14 (2008) 28-32
29. Shaffer H.J., Hall M.N., and Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 89 (1999) 1369-1376
30. Koran L.M., Faber R.J., Aboujaoude E., Large M.D., and Serpe R.T. Estimated prevalence of compulsive buying behavior in the United States. Am J Psychiatry 163 (2006) 1806-1812
31. Hudson J.I., Hiripi E., Pope Jr. H.G., and Kessler R.C. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 61 (2007) 348-358
32. Evans A.H., Lawrence A.D., Potts J., et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (2006) 317-321
33. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 75 (1972) 203-212
34. Ecker D., Unrath A., Kassubek J., and Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol 9 (2009) 23
35. Verbaan D., van Rooden S.M., Visser M., Marinus J., Emre M., and van Hilten J.J. Psychotic and compulsive symptoms in Parkinson's disease. Mov Disord 24 (2009) 738-744
36. Fenelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13 3 suppl 4 (2008) 18-25
37. Dahlstrom A., and Fuxe K. Localization of monoamines in the lower brain stem. Experientia 20 (1964) 398-399
38. Jimenez-Castellanos J., and Graybiel A.M. Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix. Neuroscience 23 (1987) 223-242
39. Haber S.N., Fudge J.L., and McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 20 (2000) 2369-2382
40. Groves P.M., Linder J.C., and Young S.J. 5-hydroxydopamine-labeled dopaminergic axons: three-dimensional reconstructions of axons, synapses and postsynaptic targets in rat neostriatum. Neuroscience 58 (1994) 593-604
41. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., and Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16 (1996) 436-447
42. Caudle W.M., Colebrooke R.E., Emson P.C., and Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 31 (2008) 303-308
43. Zahniser N.R., and Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction?. Neuropharmacology 47 suppl 1 (2004) 80-91
44. Rice M.E., and Cragg S.J. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev 58 (2008) 303-313
45. Rodriguez M., Morales I., Gomez I., Gonzalez S., Gonzalez-Hernandez T., and Gonzalez-Mora J.L. Heterogeneous dopamine neurochemistry in the striatum: the fountain-drain matrix. J Pharmacol Exp Ther 319 (2006) 31-43
46. Zoli M., Torri C., Ferrari R., et al. The emergence of the volume transmission concept. Brain Res Brain Res Rev 26 (1998) 136-147
47. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9 (2008) 665-677
48. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., and Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47 4 suppl 1 (2000) S22-S32
49. de la Fuente-Fernandez R., Sossi V., Huang Z., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (2004) 2747-2754
50. Evans A.H., Pavese N., Lawrence A.D., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59 (2006) 852-858
51. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18 (1993) 247-291
52. Silveira-Moriyama L., Evans A.H., Katzenschlager R., and Lees A.J. Punding and dyskinesias. Mov Disord 21 (2006) 2214-2217
53. Aubert I., Guigoni C., Hakansson K., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
54. Berthet A., Porras G., Doudnikoff E., et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 29 (2009) 4829-4835
55. Corvol J.C., Muriel M.P., Valjent E., et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24 (2004) 7007-7014
56. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., and Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94 (1997) 3363-3367
57. Bezard E., Ferry S., Mach U., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Med 9 (2003) 762-767
58. Morelli M., and Di Chiara G. Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. Eur J Pharmacol 141 (1987) 101-107
59. Zeng B.Y., Pearce R.K., MacKenzie G.M., and Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12 (2000) 1096-1104
60. Marcellino D., Roberts D.C., Navarro G., et al. Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal. Brain Res 1143 (2007) 208-220
61. Picconi B., Centonze D., Hakansson K., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
62. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14 (2003) 404-416
63. Metman L.V., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., and Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 (1998) 1323-1326
64. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59 (2006) 64-74
65. Santini E., Valjent E., Usiello A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27 (2007) 6995-7005
66. Schuster S., Nadjar A., Guo J.T., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 28 (2008) 4311-4316
67. Westin J.E., Vercammen L., Strome E.M., Konradi C., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-dopa-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62 (2007) 800-810
68. Bateup H.S., Svenningsson P., Kuroiwa M., et al. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11 (2008) 932-939
69. Brambilla R. Targeting Ras/ERK signaling in the striatum: will it help?. Mol Psychiatry 8 (2003) 366-368
70. Lu L., Koya E., Zhai H., Hope B.T., and Shaham Y. Role of ERK in cocaine addiction. Trends Neurosci 29 (2006) 695-703
71. Alonso-Frech F., Zamarbide I., Alegre M., et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 129 (2006) 1748-1757
72. Boraud T., Bezard E., Bioulac B., and Gross C. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alteration of pallidal neurons in the MPTP-treated monkey. Brain 124 (2001) 546-557
73. Lozano A.M., Lang A.E., Levy R., Hutchison W., and Dostrovsky J. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 47 (2000) S141-S206
74. Meissner W., Ravenscroft P., Reese R., et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine. Neurobiol Dis 22 (2006) 586-598
75. Ardouin C., Voon V., Worbe Y., et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21 (2006) 1941-1946
76. Witjas T., Baunez C., Henry J.M., et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 20 (2005) 1052-1055
77. Dagher A., and Robbins T.W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 61 (2009) 502-510
78. Benecke R., Rothwell J.C., Dick J.P., Day B.L., and Marsden C.D. Disturbance of sequential movements in patients with Parkinson's disease. Brain 110 (1987) 361-379
79. Stelmach G.E., Worringham C.J., and Strand E.A. Movement preparation in Parkinson's disease. The use of advance information. Brain 109 (1986) 1179-1194
80. Kimura M. Behaviorally contingent property of movement-related activity of the primate putamen. J Neurophysiol 63 (1990) 1277-1296
81. Brainard M.S., and Doupe A.J. Interruption of a basal ganglia-forebrain circuit prevents plasticity of learned vocalizations. Nature 404 (2000) 762-766
82. Doupe A.J., and Kuhl P.K. Birdsong and human speech: common themes and mechanisms. Annu Rev Neurosci 22 (1999) 567-631
83. Foltynie T., Brayne C.E., Robbins T.W., and Barker R.A. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127 (2003) 550-560
84. Doyon J. Motor sequence learning and movement disorders. Curr Opin Neurol 21 (2008) 478-483
85. Packard M.G., and Knowlton B.J. Learning and memory functions of the basal ganglia. Annu Rev Neurosci 25 (2002) 563-593
86. White N.M., and McDonald R.J. Multiple parallel memory systems in the brain of the rat. Neurobiol Learn Mem 77 (2002) 125-184
87. Dickinson A., Balleine B., Watt A., Gonzalez F., and Boakes R.A. Motivation control after extended instrumental training. Anim Learn Behav 23 (1995) 197-206
88. Dickinson A., Nicholas D.J., and Adams C.D. The effect of instrumental training contingency on susceptibility to reinforcer devaluation. Q J Exp Psychol B 35 (1983) 35-51
89. Divac I., Rosvold H.E., and Szwarcbart M.K. Behavioral effects of selective ablation of the caudate nucleus. J Comp Physiol Psychol 63 (1967) 184-190
90. Levine M.S., Hull C.D., Buchwald N.A., and Villablanca J.R. Effects of caudate nuclei or frontal cortical ablations in kittens: motor activity and visual discrimination performance in neonatal and juvenile kittens. Exp Neurol 62 (1978) 555-569
91. Olmstead C.E., Villablanca J.R., Marcus R.J., and Avery D.L. Effects of caudate nuclei or frontal cortex ablations in cats. IV. Bar pressing, maze learning, and performance. Exp Neurol 53 (1976) 670-693
92. McDonald R.J., and White N.M. A triple dissociation of memory systems: hippocampus, amygdala, and dorsal striatum. Behav Neurosci 107 (1993) 3-22
93. Cardinal R.N., Parkinson J.A., Hall J., and Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev 26 (2002) 321-352
94. Kelley A.E. Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci Biobehav Rev 27 (2004) 765-776
95. Yin H.H., Knowlton B.J., and Balleine B.W. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur J Neurosci 19 (2004) 181-189
96. Yin H.H., Knowlton B.J., and Balleine B.W. Inactivation of dorsolateral striatum enhances sensitivity to changes in the action-outcome contingency in instrumental conditioning. Behav Brain Res 166 (2006) 189-196
97. Faure A., Haberland U., Conde F., and El Massioui N. Lesion to the nigrostriatal dopamine system disrupts stimulus-response habit formation. J Neurosci 25 (2005) 2771-2780
98. Charbonneau D., Riopelle R.J., and Beninger R.J. Impaired incentive learning in treated Parkinson's disease. Can J Neurol Sci 23 (1996) 271-278
99. Swainson R., Rogers R.D., Sahakian B.J., Summers B.A., Polkey C.E., and Robbins T.W. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38 (2000) 596-612
100. Hollerman J.R., Tremblay L., and Schultz W. Influence of reward expectation on behavior-related neuronal activity in primate striatum. J Neurophysiol 80 (1998) 947-963
101. Lauwereyns J., Watanabe K., Coe B., and Hikosaka O. A neural correlate of response bias in monkey caudate nucleus. Nature 418 (2002) 413-417
102. Morris G., Arkadir D., Nevet A., Vaadia E., and Bergman H. Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. Neuron 43 (2004) 133-143
103. Schultz W., Apicella P., Scarnati E., and Ljungberg T. Neuronal activity in monkey ventral striatum related to the expectation of reward. J Neurosci 12 (1992) 4595-4610
104. Darbaky Y., Baunez C., Arecchi P., Legallet E., and Apicella P. Reward-related neuronal activity in the subthalamic nucleus of the monkey. Neuroreport 16 (2005) 1241-1244
105. Tang C., Pawlak A.P., Prokopenko V., and West M.O. Changes in activity of the striatum during formation of a motor habit. Eur J Neurosci 25 (2007) 1212-1227
106. Reynolds J.N., Hyland B.I., and Wickens J.R. A cellular mechanism of reward-related learning. Nature 413 (2001) 67-70
107. Wickens J.R., Begg A.J., and Arbuthnott G.W. Dopamine reverses the depression of rat corticostriatal synapses which normally follows high-frequency stimulation of cortex in vitro. Neuroscience 70 (1996) 1-5
108. Belin D., and Everitt B.J. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 57 (2008) 432-441
109. Baunez C., Dias C., Cador M., and Amalric M. The subthalamic nucleus exerts opposite control on cocaine and 'natural' rewards. Nat Neurosci 8 (2005) 484-489
110. Frank M.J., Samanta J., Moustafa A.A., and Sherman S.J. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 318 (2007) 1309-1312
111. Rodriguez-Oroz M.C., Jahanshahi M., Krack P., et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8 (2009) 1128-1139
112. Guigoni C., Li Q., Aubert I., et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 25 (2005) 2102-2107
113. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry. Brain 122 (1999) 1421-1436
114. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448